The US Food and Drug Administration has accepted for priority review the supplemental biologics license application for pembrolizumab (Keytruda) to treat patients with resectable, locally advanced ...

Patients in the reference arm were treated with 400 mg of intravenous Keytruda every six weeks plus 20 mg of daily oral lenvatinib. Across all cohorts, 100% of patients experienced any-grade side ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is a Buy.

High-risk patients in this arm also received 100 mg/m² of IV cisplatin every 3 weeks for 3 cycles ... All of the secondary end points were stratified by PD-L1 CPS status. 1 Merck’s Keytruda ...

Efficacy data revealed that between 3 arms––pembrolizumab (Keytruda)/belzutifan (n = 62 ... antiangiogenic therapies were randomly assigned 1:1 to receive either 120 mg of oral belzutifan or 10 mg of ...

The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major pathological response in patients with resectable locally advanced head and ...